|
|
|
|
|
|
|
NCCN Guidelines - Staging Evaluation and Imaging Approaches in Prostate Cancer
|
Zachary Klaassen, MD, MSc and Chris Wallis, MD, Ph.D.
Christopher Wallis and Zachary Klaassen continue their discussion on the NCCN clinical practice guidelines in oncology focusing on prostate cancer and the recently released and published update of these guidelines from September 2021. In this conversation the pair focus on questions relating to the initial clinical assessments, staging evaluation, and imaging approaches in prostate cancer.
|
|
|
|
|
|
|
|
|
| Observation and Active Surveillance in the NCCN Prostate Cancer Guidelines
|
| Zachary Klaassen, MD, MSc and Chris Wallis, MD, Ph.D.
|
| Christopher Wallis and Zachary Klaassen continue their discussion on the NCCN prostate cancer clinical practice guidelines in oncology focusing on observation and Active Surveillance (AS). The AS section of the NCCN Guidelines includes an introduction, the rationale, patient selection, confirmatory testing by discussion of an Active Surveillance program, as well as reclassification criteria.
|
|
|
|
|
|
|
|
|
|
|
| NCCN Prostate Cancer Clinical Practice Guidelines on Risk Stratification for Clinically Localized Prostate Cancer
|
| Zachary Klaassen, MD, MSc and Chris Wallis, MD, Ph.D.
|
| Christopher Wallis and Zachary Klaassen continue their in-depth review of the NCCN clinical practice guidelines in prostate cancer focusing on risk stratification for clinically localized disease. They focus on risk stratification for patients with prostate cancer.
|
|
|
|
|
|
| NCCN Guidelines on Prostate Cancer: A Focus on Chemotherapy, Immunotherapy, and Targeted Therapy in Advanced Prostate Cancer - Chemotherapeutic Approaches
|
| Zachary Klaassen, MD, MSc and Chris Wallis, MD, Ph.D.
|
| In this UroToday Journal Club presentation from Christopher Wallis and Zachary Klaassen, the pair continue their discussion on the NCCN clinical practice guidelines in oncology, with a focus on prostate cancer. This discussion is part one of a two-part series focusing on Chemotherapy, Immunotherapy, and Targeted Therapy in Advanced Prostate Cancer.
|
|
|
|
|
|
|
|
|
|
|
|
